Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
This article was originally published in The Pink Sheet Daily
Executive Summary
A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.
You may also be interested in...
FDA To Send Draft Ranexa Label Shortly
CV Therapeutics CEO is bullish on clearance in first-line angina.
FDA To Send Draft Ranexa Label Shortly
CV Therapeutics CEO is bullish on clearance in first-line angina.
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.